Does Insurance Cover a Dexcom G7 or FreeStyle Libre? The Prior-Auth Checklist, the Cheaper Channel, and the Denial That Reverses

On paper, continuous glucose monitors are among the best-covered devices in American healthcare: over 95% of private plans cover them, and Medicare covers them for every insulin user. In practice, CGM denials are one of the most common diabetes insurance fights, because coverage sits behind a prior authorization checklist, a channel choice, and a six-month chart-note clock. This guide is the whole procedure: what the checklist asks for, which door is cheaper, Medicare's exact criteria, and the counterplay when the denial letter arrives.

Does commercial insurance cover the Dexcom G7 and FreeStyle Libre?

Yes, for most people. Abbott reports Libre systems are covered by over 95% of private insurance plans, with most covered patients paying $0 to $20 a month for sensors. Dexcom reports about 87% of insulin users have coverage, with most covered people paying $20 or less a month for the G7. Coverage is strongest for type 1 and insulin-treated type 2; for type 2 without insulin it thins out (Dexcom puts non-insulin coverage near 50%, and those approvals usually require documented hypoglycemia or intensive management). The catch inside "covered": the plan agreeing that CGMs are a benefit says nothing about you yet. Your specific approval runs through prior authorization, and that is where nearly every fight starts.

What does the prior authorization checklist actually ask for?

Every plan's CGM policy is a short list of boxes, and a denial names the one the reviewer thinks is empty. The recurring items:

• A diabetes diagnosis with the right code. A vague or mismatched ICD-10 code is a common silent denial cause; the fix is clerical, at the prescriber's office.
• Your treatment regimen. Insulin use (injections or pump) approves fastest. Some commercial plans still ask for injections-per-day counts that Medicare dropped in 2023, so the note should state the regimen precisely.
• A recent visit note. Most policies want an office or telehealth visit within roughly six months that discusses your diabetes control and the CGM plan.
• Glucose evidence. Fingerstick logs, testing frequency, or documented hypoglycemia. Severe lows and readings under 54 mg/dL carry the most weight; make sure every event is actually in the chart.
• A training attestation. That you (or a caregiver) can use the device. Prescribers add this in one sentence when they know to.

Before the prescriber submits anything, call the plan and ask for its clinical policy for continuous glucose monitors. They must provide it. A chart note written to the plan's actual criteria beats a generic letter of medical necessity every time, and it is the difference between one submission and three.

Should your CGM bill through the pharmacy or the DME benefit?

The same sensor can bill through two doors, and the price difference is real. Under the pharmacy benefit, the CGM fills like a prescription: a flat drug-tier copay, picked up same-day at a retail pharmacy. Under the durable medical equipment (DME) benefit, it ships from a supplier (Byram, US Med, Edgepark and peers) with percentage coinsurance after your deductible, plus periodic re-documentation to keep shipments flowing. Early in the plan year, a flat $20 pharmacy copay usually beats 20% to 50% DME coinsurance on a full-price sensor supply; after you hit the deductible or out-of-pocket max, the gap collapses. Two questions to the plan settle it: "which benefit does my plan cover CGMs under?" and "what would I pay through each?" Many plans cover only one channel, and a claim through the wrong door denies with a code that reads like a coverage refusal when it is a routing error. That makes "which benefit did this bill under?" the first question to ask about any CGM denial.

What are Medicare's CGM requirements after the 2023 expansion?

Medicare covers CGMs (Dexcom G6/G7, FreeStyle Libre 2/3, Eversense) under Part B as durable medical equipment, and the 2023 rules made the criteria far wider than most denial letters imply:

• You qualify if you have diabetes and are treated with insulin. Any insulin, any dose, injections or pump. The old minimum-injections-per-day rule is gone.
• You also qualify without insulin if you have documented problematic hypoglycemia: more than one level 2 event (glucose under 54 mg/dL) despite treatment adjustments, or one level 3 event severe enough to need someone else's help.
• The visit clock is the trap: your practitioner must see you (in person or by Medicare-approved telehealth) within the six months before ordering, then every six months to keep coverage. Lapsed visits stop supply shipments silently.
• What you pay: 20% of the Medicare-approved amount after the 2026 Part B deductible of $283. A Medigap plan picks up that 20%, which is part of why supplement math favors people on CGMs and pumps. Use a Medicare-enrolled supplier or pharmacy, or the claim dies on enrollment status.

Medicare Advantage plans must cover at least what Original Medicare covers, so an MA denial that contradicts these criteria is built to be appealed, and those appeals overturn at high rates.

What do you do when the CGM is denied?

1. Read the denial for the named criterion. Somewhere in the letter is the specific box the reviewer marked empty: no recent visit, no documented regimen, no hypoglycemia history, wrong code. That word is your whole to-do list.
2. Check the channel before anything else. If the claim entered through the benefit your plan doesn't cover CGMs under, the fix is refiling through the right one, and no clinical argument is needed.
3. Resubmit the prior auth with the missing documentation. Get the plan's clinical policy, have the prescriber's office add exactly what it asks for (visit note, insulin regimen, logged lows), and submit fresh. This is usually faster than a formal appeal.
4. If the resubmission fails, appeal. File the internal appeal with a letter of medical necessity citing the plan's own criteria, your A1c history, and every documented hypoglycemic event. Plans must decide pre-service appeals within 30 days.
5. Then external review. An independent reviewer, free to you, with the plan bound by the result. CGM denials that contradict the plan's published policy do badly there.
6. Bridge the gap meanwhile. The manufacturer programs above keep sensors on your arm during the fight, and adults with type 2 who don't use insulin (the group commercial plans deny most) can run an over-the-counter sensor like Dexcom's Stelo, about $89 a month by subscription, without any prescription or approval at all.

One more pattern worth naming: sensors denied after an approval is on file. That is a reprocessing demand, never a bill to pay. The full counterplay, auth number and all, is in the diabetes cost stack guide.